Market research
OYST Oyster Point Pharma Inc
NASDAQ USD Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 300M
- P/E ratio
- Not available
- Analyst target
- 15
- Dividend yield
- 0.0%
- Beta
- 1.28
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology & Medical Research
- ISIN
- Not available
- Market cap
- 300M
- P/E ratio
- Not available
- Analyst target
- 15
- Dividend yield
- 0.0%
- Beta
- 1.28
About
About Oyster Point Pharma Inc
As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
Research context
Oyster Point Pharma Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology & Medical Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the OYST discussion.
5 years, 6 months ago
Oyster Point Pharma, Inc is currently in a long term downtrend where the price is trading 14.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Oyster Point Pharma, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 12.7% to $-22M since the same quarter in the previous year.
Finally, its free cash flow fell by 28.8% to $-21M since the same quarter in the previous year.
Based on the above factors, Oyster Point Pharma, Inc gets an overall score of 1/5.